Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


AEROVANCE, INC.

AEROVANCE, INC. Patent applications
Patent application numberTitlePublished
20110183920MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS - This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.07-28-2011
20110034678METHODS OF RENATURATION OF RECOMBINANT PROTEINS - The present invention provides large-scale methods for renaturation of proteins comprising adding a solution of denatured, chemically modified or reduced proteins to a refolding buffer containing sulfate derived from H02-10-2011
20090010874MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS - This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.01-08-2009

Patent applications by AEROVANCE, INC.